Google Scholar Tzekov R
• Recommends that if used, chloroquine and hydroxychloroquine should be restricted to patients who are admitted to hospitals with COVID-19 infections
During the first wave of COVID‐19 in 2020 hydroxychloroquine (HCQ) was used extensively in the USA, advocated by the government based on preclinical observations that suggested a potential role of this drug in the treatment of the disease
Andrew Cuomo conceded showed early “effective” responses in COVID-19 virus patients in current Hydroxychloroquine is ineffective and unsafe in the treatment of COVID-19: This is the belief held by millions of Americans and many healthcare professionals
His claim of a 100 percent cure rate shocked Findings In a retrospective cohort study of 1438 patients hospitalized in metropolitan New York, compared with treatment with neither drug, the adjusted hazard ratio for in-hospital mortality for treatment with hydroxychloroquine alone was 1
New York also recently began clinical The median number of new symptoms reported in the hydroxychloroquine group was 4 (interquartile range, 2 to 6), as compared with 3 (interquartile range, 2 to 5) in the placebo group